LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) shares shot up 6.3% on Thursday . The stock traded as high as $33.50 and last traded at $33.50. Approximately 43,640 shares were traded during trading, a decline of 68% from the average daily volume of 137,913 shares. The stock had previously closed at $31.50.
Several analysts have recently commented on the stock. William Blair upgraded shares of LENZ Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Raymond James began coverage on shares of LENZ Therapeutics in a report on Friday, September 27th. They set an "outperform" rating and a $37.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $35.40.
Get Our Latest Research Report on LENZ Therapeutics
The stock has a 50-day moving average of $32.07 and a 200-day moving average of $25.39.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter last year, the firm posted ($1.33) EPS. Equities analysts forecast that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in LENZ Therapeutics during the third quarter valued at approximately $107,000. MetLife Investment Management LLC bought a new stake in LENZ Therapeutics in the third quarter valued at about $182,000. GSA Capital Partners LLP acquired a new position in shares of LENZ Therapeutics in the 3rd quarter worth approximately $246,000. Squarepoint Ops LLC acquired a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at $181,000. Finally, Jane Street Group LLC bought a new stake in shares of LENZ Therapeutics in the 3rd quarter worth about $286,000. 54.32% of the stock is currently owned by hedge funds and other institutional investors.
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.